Vaccination with a Modified Vaccinia Virus Ankara‐based vaccine protects mice from allergic sensitization
Identifieur interne : 003249 ( Main/Exploration ); précédent : 003248; suivant : 003250Vaccination with a Modified Vaccinia Virus Ankara‐based vaccine protects mice from allergic sensitization
Auteurs : Melanie Albrecht [Allemagne] ; Yasemin Suezer [Allemagne] ; Caroline Staib [Allemagne] ; Gerd Sutter [Allemagne] ; Stefan Vieths [Allemagne] ; Gerald Reese [Allemagne]Source :
- The Journal of Gene Medicine [ 1099-498X ] ; 2008-12.
Abstract
Background: Currently, no treatment is available for food allergy and strict avoidance of the allergenic food remains the only way to manage the allergy. New strategies leading to a safe and efficacious food allergy treatment are required. Modified vaccinia virus Ankara (MVA), which allows high levels of expression of recombinant protein in vivo and gives rise to a Th1‐biased specific immune response, was used as a prophylactic vaccine in a murine model of ovalbumin (OVA) allergy. Methods: An MVA‐OVA vector vaccine was prepared. Female BALB/c mice were vaccinated twice with a MVA‐OVA vector vaccine, followed by sensitization with OVA plus alum. OVA‐specific immunoglobulin E(IgE) activity was measured by mediator release from rat basophilic leukaemia cells, whereas specific IgG subclass titers were determined by enzyme‐linked immunosorbent assay. Results: Expression of immunological active OVA in mammalian cells was demonstrated. OVA‐specific IgE levels in sera from MVA‐OVA‐vaccinated mice were reduced and appeared delayed. The vaccine‐mediated immune modulation was dose‐dependent; the highest vaccine dose protected 50% of the animals from allergic sensitization. Upon sensitization, similar OVA‐specific IgG1 titers were found in all mice, but the OVA‐specific IgG2a antibody levels were strongly increased in MVA‐OVA‐vaccinated mice, signifying a Th1‐biased and, non‐allergic immune response. Conclusions: Prophylactic vaccination with MVA‐OVA delays and in part even prevents the onset of a successful allergen‐specific sensitization. Recombinant MVA, which fulfills the requirements for clinical application, is a promising candidate vector for the development of novel approaches to allergen‐specific prophylactic vaccination and specific immunotherapy. Copyright © 2008 John Wiley & Sons, Ltd.
Url:
DOI: 10.1002/jgm.1256
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001924
- to stream Istex, to step Curation: 001924
- to stream Istex, to step Checkpoint: 000F23
- to stream Main, to step Merge: 003351
- to stream Main, to step Curation: 003249
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vaccination with a Modified Vaccinia Virus Ankara‐based vaccine protects mice from allergic sensitization</title><author><name sortKey="Albrecht, Melanie" sort="Albrecht, Melanie" uniqKey="Albrecht M" first="Melanie" last="Albrecht">Melanie Albrecht</name></author><author><name sortKey="Suezer, Yasemin" sort="Suezer, Yasemin" uniqKey="Suezer Y" first="Yasemin" last="Suezer">Yasemin Suezer</name></author><author><name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name></author><author><name sortKey="Sutter, Gerd" sort="Sutter, Gerd" uniqKey="Sutter G" first="Gerd" last="Sutter">Gerd Sutter</name></author><author><name sortKey="Vieths, Stefan" sort="Vieths, Stefan" uniqKey="Vieths S" first="Stefan" last="Vieths">Stefan Vieths</name></author><author><name sortKey="Reese, Gerald" sort="Reese, Gerald" uniqKey="Reese G" first="Gerald" last="Reese">Gerald Reese</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B1FFBD3F112DE86588209048C9D53A2CB04ED661</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/jgm.1256</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-JVHGJKP8-Q/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001924</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001924</idno><idno type="wicri:Area/Istex/Curation">001924</idno><idno type="wicri:Area/Istex/Checkpoint">000F23</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000F23</idno><idno type="wicri:doubleKey">1099-498X:2008:Albrecht M:vaccination:with:a</idno><idno type="wicri:Area/Main/Merge">003351</idno><idno type="wicri:Area/Main/Curation">003249</idno><idno type="wicri:Area/Main/Exploration">003249</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Vaccination with a Modified Vaccinia Virus Ankara‐based vaccine protects mice from allergic sensitization</title><author><name sortKey="Albrecht, Melanie" sort="Albrecht, Melanie" uniqKey="Albrecht M" first="Melanie" last="Albrecht">Melanie Albrecht</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Paul‐Ehrlich‐Institut, Department of Allergology, Langen</wicri:regionArea><wicri:noRegion>Langen</wicri:noRegion><wicri:noRegion>Langen</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Paul‐Ehrlich‐Institut, Department of Virology, Langen</wicri:regionArea><wicri:noRegion>Langen</wicri:noRegion><wicri:noRegion>Langen</wicri:noRegion></affiliation></author><author><name sortKey="Suezer, Yasemin" sort="Suezer, Yasemin" uniqKey="Suezer Y" first="Yasemin" last="Suezer">Yasemin Suezer</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Paul‐Ehrlich‐Institut, Department of Virology, Langen</wicri:regionArea><wicri:noRegion>Langen</wicri:noRegion><wicri:noRegion>Langen</wicri:noRegion></affiliation></author><author><name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name><affiliation wicri:level="4"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Virology, Technical University of Munich</wicri:regionArea><placeName><settlement type="city">Munich</settlement><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region></placeName><orgName type="university">Université Louis-et-Maximilien de Munich</orgName></affiliation></author><author><name sortKey="Sutter, Gerd" sort="Sutter, Gerd" uniqKey="Sutter G" first="Gerd" last="Sutter">Gerd Sutter</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Paul‐Ehrlich‐Institut, Department of Virology, Langen</wicri:regionArea><wicri:noRegion>Langen</wicri:noRegion><wicri:noRegion>Langen</wicri:noRegion></affiliation></author><author><name sortKey="Vieths, Stefan" sort="Vieths, Stefan" uniqKey="Vieths S" first="Stefan" last="Vieths">Stefan Vieths</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Paul‐Ehrlich‐Institut, Department of Allergology, Langen</wicri:regionArea><wicri:noRegion>Langen</wicri:noRegion><wicri:noRegion>Langen</wicri:noRegion></affiliation></author><author><name sortKey="Reese, Gerald" sort="Reese, Gerald" uniqKey="Reese G" first="Gerald" last="Reese">Gerald Reese</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Paul‐Ehrlich‐Institut, Department of Allergology, Langen</wicri:regionArea><wicri:noRegion>Langen</wicri:noRegion><wicri:noRegion>Langen</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Allemagne</country></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Correspondence address: Paul‐Ehrlich‐Institut, Department of Allergology, Paul‐Ehrlich‐Strasse 51‐59, D‐63225 Langen</wicri:regionArea><wicri:noRegion>63225 Langen</wicri:noRegion><wicri:noRegion>D‐63225 Langen</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">The Journal of Gene Medicine</title><title level="j" type="alt">JOURNAL OF GENE MEDICINE, THE</title><idno type="ISSN">1099-498X</idno><idno type="eISSN">1521-2254</idno><imprint><biblScope unit="vol">10</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1324">1324</biblScope><biblScope unit="page" to="1333">1333</biblScope><biblScope unit="page-count">10</biblScope><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2008-12">2008-12</date></imprint><idno type="ISSN">1099-498X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1099-498X</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Currently, no treatment is available for food allergy and strict avoidance of the allergenic food remains the only way to manage the allergy. New strategies leading to a safe and efficacious food allergy treatment are required. Modified vaccinia virus Ankara (MVA), which allows high levels of expression of recombinant protein in vivo and gives rise to a Th1‐biased specific immune response, was used as a prophylactic vaccine in a murine model of ovalbumin (OVA) allergy. Methods: An MVA‐OVA vector vaccine was prepared. Female BALB/c mice were vaccinated twice with a MVA‐OVA vector vaccine, followed by sensitization with OVA plus alum. OVA‐specific immunoglobulin E(IgE) activity was measured by mediator release from rat basophilic leukaemia cells, whereas specific IgG subclass titers were determined by enzyme‐linked immunosorbent assay. Results: Expression of immunological active OVA in mammalian cells was demonstrated. OVA‐specific IgE levels in sera from MVA‐OVA‐vaccinated mice were reduced and appeared delayed. The vaccine‐mediated immune modulation was dose‐dependent; the highest vaccine dose protected 50% of the animals from allergic sensitization. Upon sensitization, similar OVA‐specific IgG1 titers were found in all mice, but the OVA‐specific IgG2a antibody levels were strongly increased in MVA‐OVA‐vaccinated mice, signifying a Th1‐biased and, non‐allergic immune response. Conclusions: Prophylactic vaccination with MVA‐OVA delays and in part even prevents the onset of a successful allergen‐specific sensitization. Recombinant MVA, which fulfills the requirements for clinical application, is a promising candidate vector for the development of novel approaches to allergen‐specific prophylactic vaccination and specific immunotherapy. Copyright © 2008 John Wiley & Sons, Ltd.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Bavière</li><li>District de Haute-Bavière</li></region><settlement><li>Munich</li></settlement><orgName><li>Université Louis-et-Maximilien de Munich</li></orgName></list><tree><country name="Allemagne"><noRegion><name sortKey="Albrecht, Melanie" sort="Albrecht, Melanie" uniqKey="Albrecht M" first="Melanie" last="Albrecht">Melanie Albrecht</name></noRegion><name sortKey="Albrecht, Melanie" sort="Albrecht, Melanie" uniqKey="Albrecht M" first="Melanie" last="Albrecht">Melanie Albrecht</name><name sortKey="Reese, Gerald" sort="Reese, Gerald" uniqKey="Reese G" first="Gerald" last="Reese">Gerald Reese</name><name sortKey="Reese, Gerald" sort="Reese, Gerald" uniqKey="Reese G" first="Gerald" last="Reese">Gerald Reese</name><name sortKey="Reese, Gerald" sort="Reese, Gerald" uniqKey="Reese G" first="Gerald" last="Reese">Gerald Reese</name><name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name><name sortKey="Suezer, Yasemin" sort="Suezer, Yasemin" uniqKey="Suezer Y" first="Yasemin" last="Suezer">Yasemin Suezer</name><name sortKey="Sutter, Gerd" sort="Sutter, Gerd" uniqKey="Sutter G" first="Gerd" last="Sutter">Gerd Sutter</name><name sortKey="Vieths, Stefan" sort="Vieths, Stefan" uniqKey="Vieths S" first="Stefan" last="Vieths">Stefan Vieths</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003249 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003249 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:B1FFBD3F112DE86588209048C9D53A2CB04ED661
|texte= Vaccination with a Modified Vaccinia Virus Ankara‐based vaccine protects mice from allergic sensitization
}}
| This area was generated with Dilib version V0.6.33. |  |